Scientists from Sweden's Karolinska Institute and Britain's Cambridge University said more studies are needed to determine if the use of CRISPR-Cas9 gene-editing technology could raise the risk of cancer developing due to potential malfunction of the p53 gene. Their research papers were published in the journal Nature Medicine.
Studies see potential for cancer risk in CRISPR-Cas9 therapies
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.